{"nctId":"NCT01916967","briefTitle":"An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201)","startDateStruct":{"date":"2013-08-27","type":"ACTUAL"},"conditions":["Urticaria"],"count":239,"armGroups":[{"label":"Desloratadine 5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Desloratadine","Drug: Placebo"]},{"label":"Desloratadine 10 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Desloratadine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Desloratadine","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Chronic urticaria \\[rash (erythema, wheal) for more than 1 month without any known cause\\]\n* Out-patient\n\nExclusion Criteria:\n\n* Stimulation-induced urticaria \\[physical urticaria (e.g. cold, solar, and heat urticaria), cholinergic urticaria, contact urticaria)\\]\n* Hypersensitivity to antihistamines or ingredients of a study drug","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in the Sum Score of Pruritus/Itch and Rash Assessed by Investigator at Week 2","description":"The Investigator assessed the severity of participant pruritus/itch during the daytime (0=Virtually no itching to 4=Cannot relax because of constant itching) and nighttime (0=Virtually no itching to 4=Cannot sleep because of itching). The score used for pruritus/itch was the higher of the day or night scores (0=Asymptomatic to 4=Severe). The Investigator also assessed the severity of participant rash using the overall rash score (0=No rash to 3=Looks very bad). The sum of the pruritus/itch score (0-4) and rash score (0-3) could range from 0 to 7, with a higher sum score indicating greater severity. The change from Baseline in the sum of the pruritus/itch and overall rash scores at the Week 2 clinic visit was calculated.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.19","spread":null},{"groupId":"OG001","value":"-3.16","spread":null},{"groupId":"OG002","value":"-2.02","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Experienced at Least One Adverse Event (AE)","description":"An AE is any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the study drug, is also an AE.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"16","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Discontinued Study Drug Due to an AE","description":"An AE is any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug or protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that is temporally associated with the use of the study drug, is also an AE.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Sum Score of Pruritus/Itch and Rash Assessed by Investigator at Day 3 and Week 1","description":"The Investigator assessed the severity of participant pruritus/itch during the daytime (0=Virtually no itching to 4=Cannot relax because of constant itching) and nighttime (0=Virtually no itching to 4=Cannot sleep because of itching). The score used for pruritus/itch was the higher of the day or night scores (0=Asymptomatic to 4=Severe). The Investigator also assessed the severity of participant rash using the overall rash score (0=No rash to 3=Looks very bad). The sum of the pruritus/itch score (0-4) and rash score (0-3) could range from 0 to 7, with a higher sum score indicating greater severity. The changes from Baseline in the sum of the pruritus/itch and overall rash scores at the Day 3 and Week 1 clinic visits were calculated.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.57","spread":null},{"groupId":"OG001","value":"-2.75","spread":null},{"groupId":"OG002","value":"-0.80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.01","spread":null},{"groupId":"OG001","value":"-3.16","spread":null},{"groupId":"OG002","value":"-1.39","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Pruritus/Itch Score Assessed by Investigator at Day 3, Week 1 and Week 2","description":"The Investigator assessed the severity of participant pruritus/itch during the daytime and nighttime (0=Asymptomatic to 4=Severe). The sum of the daytime and nighttime pruritus/itch scores could range from 0 to 8, with a higher score indicating greater severity. The changes from Baseline in the sum of the daytime and nighttime scores at the Day 3, Week 1 and Week 2 clinic visits were calculated.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.62","spread":null},{"groupId":"OG001","value":"-2.72","spread":null},{"groupId":"OG002","value":"-0.61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.98","spread":null},{"groupId":"OG001","value":"-3.13","spread":null},{"groupId":"OG002","value":"-1.38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.17","spread":null},{"groupId":"OG001","value":"-3.21","spread":null},{"groupId":"OG002","value":"-1.91","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Rash Score Assessed by Investigator at Day 3, Week 1 and Week 2","description":"The Investigator assessed the severity of participant rash (erythema: 0=no symptom to 3=intensive redness, and wheal: 0=no symptom to 3=significant ridge). The sum score for erythema plus wheal could range from 0 to 6, with a higher score indicating greater severity. The changes from Baseline in the sum score for erythema plus wheal at the Day 3, Week 1 and Week 2 clinic visits were calculated.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.31","spread":null},{"groupId":"OG001","value":"-2.61","spread":null},{"groupId":"OG002","value":"-0.99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.65","spread":null},{"groupId":"OG001","value":"-2.98","spread":null},{"groupId":"OG002","value":"-1.44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.94","spread":null},{"groupId":"OG001","value":"-2.91","spread":null},{"groupId":"OG002","value":"-1.98","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Moderate or Remarkable Improvement in the Global Improvement Rate of Both Pruritus/Itch and Rash (Erythema and Wheal) Assessed by the Investigator at Day 3, Week 1 and Week 2","description":"The global improvement judgment criteria were used to assess overall improvement in pruritus/itch and rash. The Investigator assessed participant global improvement according to 5 grades (Grade 1=Remarkable improvement to Grade 5=Aggravated). The number of participants with moderate or remarkable improvements was calculated. Remarkable improvement (Grade 1) was defined as both pruritus/itch and rash (erythema and wheal) disappeared, or pruritus/itch disappeared and rash (erythema and wheal) was apparently improved. Moderate improvement (Grade 2) was defined as both pruritus/itch and rash (erythema and wheal) were greatly improved.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"58","spread":null},{"groupId":"OG002","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"53","spread":null},{"groupId":"OG002","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Pruritus/Itch Score Reported in Participant Diaries at Day 3, Week 1 and Week 2","description":"Participants assessed the severity of their pruritus/itch during the daytime and nighttime (0=asymptomatic to 4=severe). The sum of the daytime and nighttime pruritus/itch scores could range from 0 to 8, with a higher score indicating greater severity. The changes from Baseline in the sum of the daytime and nighttime scores at the Day 3, Week 1 and Week 2 clinic visits were calculated.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.37","spread":null},{"groupId":"OG001","value":"-2.73","spread":null},{"groupId":"OG002","value":"-0.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.53","spread":null},{"groupId":"OG001","value":"-2.85","spread":null},{"groupId":"OG002","value":"-1.27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.85","spread":null},{"groupId":"OG001","value":"-2.97","spread":null},{"groupId":"OG002","value":"-1.75","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Pruritus/Itch on a Visual Analog Scale (VAS) Reported by Participants at Day 3, Week 1 and Week 2","description":"Participants assessed the degree of their pruritus/itching using a 100-mm visual analog scale (VAS) (0 mm=No itch to 100 mm=Worst imaginable itch), with a higher score indicating more severe itching. The changes from Baseline in participant-assessed pruritus/itch at the Day 3, Week 1 and Week 2 clinic visits were calculated.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.94","spread":null},{"groupId":"OG001","value":"-39.60","spread":null},{"groupId":"OG002","value":"-5.22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.82","spread":null},{"groupId":"OG001","value":"-48.82","spread":null},{"groupId":"OG002","value":"-15.88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.86","spread":null},{"groupId":"OG001","value":"-45.01","spread":null},{"groupId":"OG002","value":"-25.24","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Rash Score Reported in Participant Diaries at Day 3, Week 1 and Week 2","description":"Participants assessed the severity of their rash (erythema: 0=no symptom to 3=intensive redness, and wheal: 0=no symptom to 3=significant ridge). The sum score for erythema plus wheal could range from 0 to 6, with a higher score indicating greater severity. The changes from Baseline in the sum score for erythema plus wheal at the Day 3, Week 1 and Week 2 clinic visits were calculated.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.21","spread":null},{"groupId":"OG001","value":"-2.31","spread":null},{"groupId":"OG002","value":"-0.77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.15","spread":null},{"groupId":"OG001","value":"-2.43","spread":null},{"groupId":"OG002","value":"-1.17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.51","spread":null},{"groupId":"OG001","value":"-2.45","spread":null},{"groupId":"OG002","value":"-1.70","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score Reported by Participants at Week 1 and Week 2","description":"The DLQI is a 10-item questionnaire that measures how much participant skin problems have affected their life. Responses to questions about the effect of participant skin problems on life ranged from 0=Not at all to 3=Very much. The DLQI is broken down into 6 subscales: Symptoms and feelings (range 0-6), Daily activities (range 0-6), Leisure (range 0-6), Work and school (range 0-3), Personal relationships (range 0-6), and Treatment (range 0-3). DLQI subscales were summed to yield the DLQI total score, which could range from 0 to 30. For both DLQI subscales and DLQI total score, a higher score indicated a greater negative impact on life. Participants \\>=16 years of age completed the DLQI questionnaire about the condition of their skin over the previous week. The changes from Baseline in the DLQI total score at the Week 1 and Week 2 clinic visits were calculated.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.82","spread":null},{"groupId":"OG001","value":"-4.08","spread":null},{"groupId":"OG002","value":"-1.60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.10","spread":null},{"groupId":"OG001","value":"-4.01","spread":null},{"groupId":"OG002","value":"-2.53","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":80},"commonTop":["Nasopharyngitis","Somnolence"]}}}